Arjun Sahgal MD
MD, FRCPC, Scientist
•B.Sc., 1997, faculty of science, University of Ottawa, Canada
•MD, 2001, faculty of medicine, University of Ottawa, Canada
•Resident, 2006, department of radiation oncology, University of Toronto, Canada
•Clinical fellow, 2007, department of radiation oncology, University of California, U.S.
Appointments and Affiliations:
•Staff radiation oncologist, department of radiation oncology, Sunnybrook Health Sciences Centre
•Professor, department of radiation oncology, U of T
•Radiosurgery of brain and spine metastases
•Advanced imaging of brain metastases and response determination
•Spinal cord tolerance to radiation
•Vertebral compression fracture
Dr. Sahgal’s research relates to his training and clinical expertise in spinal metastases, brain metastases and primary central nervous system tumours. He has expertise in the technical evaluation of radiation apparatus, and in developing and conducting clinical trials specific to brain radiosurgery and stereotactic body radiotherapy for spinal metastases.
Dr. Sahgal’s main interest is in fundamental technical research and development specific to MR-linac technology, Gamma Knife technology and the general application of stereotactic radiation. In line with high-precision radiotherapy treatments, Dr. Sahgal participates in the development of focal nonradiotherapeutic modalities for spine and brain tumours using photodynamic therapy, radiofrequency ablation and MRI-guided ultrasound.
- Gaebe K, Li AY, Park A, Parmar A, Lok BH, Sahgal A, Chan KKW, Erickson AW, Das S. Stereotactic radiosurgery versus whole brain radiotherapy in patients with intracranial metastatic disease and small cell lung cancer, a systematic review and meta-analysis Lancet Oncol. 2022 Jul;23(7):931-939. doi: 10.1016/S1470-2045(22)00271-6. Epub 2022 May 26. PMID: 35644163.
- Tan H, Stewart J, Ruschin M, Wang MH, Myrehaug S, Tseng CL, Detsky J, Husain Z, Chen H, Sahgal A, Soliman H. Inter-fraction dynamics during post-operative 5 fraction cavity hypofractionated stereotactic radiotherapy with a MR LINAC J Neurooncol. 2022 Feb;156(3):569-577. doi: 10.1007/s11060-021-03938-w. Epub 2022 Jan 3. PMID: 34981300.
- Tseng CL, Chen H, Stewart J, Lau AZ, Chan RW, Lawrence LSP, Myrehaug S, Soliman H, Detsky J, Lim-Fat MJ, Lipsman N, Das S, Heyn C, Maralani PJ, Binda S, Perry J, Keller B, Stanisz GJ, Ruschin M, Sahgal A. High grade glioma radiation therapy on a high field 1.5 Tesla MR-Linac – workflow and initial experience with daily adapt-to-position (ATP) MR guidance A first report Front Oncol. 2022 Nov 28;12:1060098. doi: 10.3389/fonc.2022.1060098. PMID: 36518316; PMCID: PMC9742425.
- Wang MH, Kim A, Ruschin M, Tan H, Soliman H, Myrehaug S, Detsky J, Husain Z, Atenafu EG, Keller B, Sahgal A, Tseng CL. Comparison of Prospectively Generated Glioma Treatment Plans Clinically Delivered on Magnetic Resonance Imaging (MRI)-Linear Accelerator (MR-Linac) Versus Conventional Linac: Predicted and Measured Skin Dose. Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338221124695. doi: 10.1177/15330338221124695. PMID: 36071647; PMCID: PMC9459463.
- Versteeg AL, Elkaim LM, Sahgal A, Rhines LD, Sciubba DM, Schuster JM, Fehlings MG, Lazary A, Clarke MJ, Arnold PM, Bettegowda C, Boriani S, Gokaslan ZL, Fisher CG, Weber MH; AO Spine Knowledge Forum Tumor. Steroids in the Management of Preoperative Neurological Deficits in Metastatic Spine Disease, Results From the EPOSO Study Neurospine. 2022 Mar;19(1):43-50. doi: 10.14245/ns.2142768.384. Epub 2022 Jan 30. PMID: 35130426; PMCID: PMC8987562.